Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actinium-J591 in PSMA-Detected Metastatic Hormone-Sensitive Recurrent Prostate Cancer
NCT05567770Phase 1Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of CONV01-α in prostate cancer (PCa) (2 cohorts), sponsored by Weill Cornell Medicine. Primary endpoints: Dose Limiting Toxicity Rate at 24 months and Change in Maximum Tolerated Dose at 24 months. Planned start Dec 2023; status: withdrawn.
02
Drugs
CONV01-α
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05567770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567770.